Health Technology · Pharmaceuticals: Major · NSE: GLAND · data 2026-10-09
Gland Pharma Ltd.
Health check: Strong (7.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹3,061.8
Market cap
₹50,657 cr
P/E
44.7
P/B
—
ROE
10.5%
ROCE
12.0%
Debt / equity
0.03
Dividend yield
0.65%
1-year return
56.6%
52-week high
₹3,171
52-week low
₹1,573.6
Operating margin
19.6%
Growth
| Revenue (last 12 months) | ₹6,725 cr |
| Net profit (last 12 months) | ₹1,129 cr |
| Sales growth, 3 years (yearly) | 21.1% |
| Profit growth, 3 years (yearly) | 9.6% |
Similar companies
Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · IPCA Laboratories Limited (IPCALAB) · Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLAND in NSE Scanner →